Levetiracetam Brillpharma

Levetiracetam, the active ingredient in Levetiracetam Brillpharma, is an anticonvulsant presented as an oral tablet for systemic use. It is employed to control various seizure types in patients with epilepsy, including partial‑onset, generalized tonic‑clonic, and myoclonic seizures, helping to reduce neuronal hyper‑excitability and improve patients' quality of life. The medication is administered orally and is absorbed systemically, providing consistent plasma concentrations suitable for long‑term management.

GNH USA supplies Levetiracetam Brillpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an anticonvulsant used to treat seizure disorders. - Partial‑onset seizures: reduces the frequency and severity of focal seizures in patients with epilepsy, improving daily functioning. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in generalized epilepsy, decreasing risk of injury and hospitalization. - Myoclonic seizures: controls rapid, involuntary muscle jerks associated with myoclonic epilepsy, aiding in maintaining motor control. - Adjunct therapy: can be combined with other antiepileptic drugs to enhance seizure control when monotherapy is insufficient.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to severe. Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or lacking energy. - Headache: mild to moderate cranial pain. - Nausea: upset stomach possibly with vomiting. - Irritability: mood changes or increased agitation. - Somnolence: excessive sleepiness during the day. - Blurred vision: temporary visual disturbances. - Coordination problems: difficulty with fine motor tasks. Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood or behavior changes: depression, suicidal thoughts, or aggression. - Hematologic abnormalities: low blood cell counts such as leukopenia or thrombocytopenia. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Stevens‑Johnson syndrome: rare severe skin reaction. - Rash with blistering: toxic epidermal necrolysis. - Severe depression: persistent low mood requiring intervention. - Multiorgan failure: extremely rare systemic involvement.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal function: adjust dose in patients with impaired kidney function. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Psychiatric history: observe for worsening mood or suicidal ideation. - Pregnancy: evaluate risk‑benefit as safety data are limited. - Driving and machinery: advise patients about possible dizziness or drowsiness affecting performance. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety profile. Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing efficacy. - Phenobarbital: can lower levetiracetam concentrations, requiring close monitoring. Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression may increase dizziness or sedation. - Other antiepileptics (e.g., valproate, phenytoin): may require dose adjustments based on therapeutic monitoring. - Oral contraceptives: levetiracetam may slightly reduce hormonal efficacy, consider alternative contraception. - Antidepressants (e.g., SSRIs): monitor for increased irritability or mood changes.